Einstein
We have identified oxytocin as a novel and powerful anti-obesity agent; we propose to form a company to develop the next-generation oxytocin analogs with improved properties. Team: Sudarshana Purkavastha
Read MoreZLife Technologies
We have developed and patented a novel preservation solution to be used as a clinical treatment for ischemia-reperfusion injury in organ transplantation, particularly intestinal transplantation. Team: Ming Zhang, MD, PhD. – President, CEO Xiang Li Andrew Hitchings
Read MoreAIdentyfy
AIdentyfy is a healthcare software company that offers machine learning-based digital solutions that have been developed by physicians for physicians. Team: Samuel K. Cho, MD Eric K. Oermann, MD Jun S. Kim, MD
Read MoreLanyard Therapeutics
We are developing a first-in-class and best-in-class biologics for mechanism-based cancer immunotherapy Lanyard Theraputics Team: Ming Li Dr. Xiuyan Wang Douglas Zhang
Read MoreChylos, Inc.
We have discovered a microRNA, miR-30c, which lowers plasma cholesterol and atherosclerosis in mice. We would like to commercialize it as a drug to treat hyperlipidemia and atherosclerosis. Chylos, Inc. Team: Mahmood Hussain
Read MoreNew York R&D Center for Translational Medicine and Therapeutics, Inc. (Ny.TmT)
The product we’re developing is provides an intervention for tendon and ligament injury repair and regeneration and tendinopathy treatment. New York R&D Center for Translational Medicine and Therapeutics, Inc. (Ny.TmT) Team: Herb Sun Angela Wang Daniel Leong
Read MoreKures, inc.
I am developing improved analogs of the known antidepressant, tianeptine, which acts through a novel mechanism of action, as new therapies for treatment-resistant depression. Kures, Inc. Team: Andrew Kruegel
Read MoreLandos Biopharma
Landos Biopharma (formerly Biotherapeutics) is a science-based company that is advancing novel, oral, small molecules to treat inflammation and diabetes towards IND and clinical trials. Landos Biopharma Team: Adria Carbo Josep Bassaganya-Riera
Read MoreTirgan BioPharmaceuticals
Focusing on developing new drugs for treatment of Keloid Disorder: 1) reformulating a generic drug into a sustained release product using nano-technology; 2) purifying plant extract to create a new topical cream. Tirgan BioPharmaceuticals Team: Michael Tirgan
Read MoreImmuneTarget, Inc.
Our mission at ImmuneTarget is to develop novel Rel/NF-kB inhibitor drugs for cancer and autoimmune diseases. ImmuneTarget, Inc. Team: Hsiou-Chi Liou Samedy Ouk
Read More